M. D. Anderson Cancer Center SPORE in Multiple Myeloma

多发性骨髓瘤是一种克隆性浆细胞恶性肿瘤，尽管最近的治疗进展，但在美国患有这种疾病的59，000多名患者中的绝大多数患者中仍然无法治愈。因此，德克萨斯大学M。D.安德森癌症中心与宾夕法尼亚大学和弗吉尼亚联邦大学合作，提出了这个多发性骨髓瘤卓越研究（SPORE）的专业计划。该计划的主要目标是将有前途的新策略从实验室转化为床边，以降低多发性骨髓瘤患者的发病率和死亡率，并提高其生活质量。为此，一个由经验丰富的研究人员组成的多学科协作小组将开展四个高度创新的项目： 项目1 -骨髓瘤的联合活化T细胞和疫苗治疗（Kwak/Giralt/June/Stadtmauer） 项目2 -抗β 2-微球蛋白抗体作为多发性骨髓瘤的治疗药物（Yi/Wang）项目3-靶向HDM-2 E3连接酶治疗多发性骨髓瘤（Orlowski/Weber） 项目4 -通过联合CDK抑制剂和Bcl-2拮抗剂靶向多发性骨髓瘤（Grant/Wang/Dai/Dent） 为了提供最大限度地提高项目成功率所需的专业知识，它们将得到五个核心设施的支持： 核心A -行政核心设施（Orlowski/Kwak） 核心B -骨髓瘤组织核心机构（Kornblau/Wang/Davis/Lin） 核心C -动物模型核心机构（Yi/Yang） 核心D -临床试验核心机构（Weber/Stadtmauer/McLaughlin） 核心E -生物统计学和生物信息学核心设施（Berry/Baladandayuthapani/Almeida/ Ramakrishnan） 此外，SPORE将通过以下项目吸引新的研究人员，并培养下一代骨髓瘤研究人员： 发展研究计划（OrlowskiA 'i） 职业发展方案（Kwak/Aggarwal/Stadtmauer） 因此，这个孢子将作为其研究者和骨髓瘤研究界的纽带，以促进必要的多学科努力，使我们更接近治愈这种疾病。

Multiple myeloma is a clonal plasma cell malignancy which, despite recent treatment advances, remains incurable in the vast majority of the over 59,000 patients in the United States afflicted with this disease. Therefore, The University of Texas M. D. Anderson Cancer Center, in collaboration with The University of Pennsylvania and the Virginia Commonwealth University, is proposing this Specialized Program of Research Excellence (SPORE) in Multiple Myeloma. The primary goal of this program will be to translate promising new strategies from the bench to the bedside to reduce the morbidity and mortality, and improve the quality of life of multiple myeloma patients. To do so, a multidisciplinary, collaborative group of experienced investigators will be pursuing four highly innovative Projects: Project 1 - Combination Activated T-Cell and Vaccine Therapy in Myeloma (Kwak/Giralt/June/Stadtmauer) Project 2 - Anti-(32-microglobulin Antibodies as Therapeutic Agents for Multiple Myeloma (Yi/Wang) Project 3-Targeting the HDM-2 E3 Ligase in Multiple Myeloma (Orlowski/Weber) Project 4 - Targeting Multiple Myeloma by Combining CDK Inhibitors and Bcl-2 Antagonists (Grant/Wang/Dai/Dent) To provide the specialized expertise needed to maximize the success of the Projects, they will be supported by five Core Facilities: Core A - Administrative Core Facility (Orlowski/Kwak) Core B - Myeloma Tissue Core Facility (Kornblau/Wang/Davis/Lin) Core C - Animal Models Core Facility (Yi/Yang) Core D - Clinical Trials Core Facility (Weber/Stadtmauer/McLaughlin) Core E - Biostatistics and Bioinformatics Core Facility (Berry/Baladandayuthapani/Almeida/ Ramakrishnan) Also, the SPORE will attract new investigators with additional novel ideas, and train the next generation of myeloma researchers, through the following Programs: Developmental Research Program (OrlowskiA'i) Career Development Program (Kwak/Aggarwal/Stadtmauer) This SPORE will therefore serve as a nexus for its Investigators and the myeloma research community to foster the kind of multidisciplinary efforts that are necessary to bring us closer to a cure for this disease.